PIII — P3 Health Partners Inc.

P3 Health Partners Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Membership: Approximately 116,000 members, consistent with expectations.
• Capitated Revenue: $341.6 million, approximately $982 per member per month (PMPM).
• Adjusted EBITDA Loss: $45.9 million for the quarter; year-to-date loss of $85.2 million. Normalized adjusted EBITDA loss year-to-date was approximately $70 million.
• Medical Margin: $4.4 million for the quarter ($13 PMPM), up from $500,000 ($1 PMPM) in the prior year. Year-to-date medical margin was $52.2 million ($50 PMPM).
• Operating Expenses: Reduced to $21.1 million from $31.6 million year-over-year, reflecting a 33% improvement.

2. Strategic Updates and Business Highlights:

• Focus on stabilizing operations, enhancing clinical foundations, and improving provider alignment.
• Capitated revenue increased by 6%, with normalized medical cost trends remaining flat year-over-year.
• Operational improvement plan has led to over $100 million in EBITDA improvement year-over-year.
• Strategic joint venture expected to add approximately 13,000 fully accretive ACO members.
• Continued rationalization of the provider network to enhance margin performance.

3. Forward Guidance and Outlook:

• Revised full-year adjusted EBITDA guidance to a loss range of $110 million to $95 million, reflecting current performance expectations.
• Anticipated EBITDA expansion opportunities of $120 million to $170 million for 2026, driven by improved provider alignment, scaling clinical programs, and contractual adjustments.
• Positive macroeconomic trends expected to benefit the business, including favorable rate environments from CMS.

4. Bad News, Challenges, or Points of Concern:

• The company experienced unfavorable midyear settlements, resulting in a $24 million impact in Q3.
• Ongoing challenges with one specific payor and market continue to affect performance.
• The need for improved visibility and predictability in claims and settlements remains a concern, with potential risks of further prior period adjustments in 2026.
• Despite operational improvements, the company is still navigating a transitional year, indicating ongoing instability.

5. Notable Q&A Insights:

• Management discussed the motivation for payors to renegotiate contracts, emphasizing the need for better outcomes in managing high-risk patients.
• The guidance reduction was attributed to broader issues rather than a single payor or market.
• Future expectations for PMPM revenue growth include a 5% net improvement in premium rates, with additional benefits expected from improved coding.
• Management expressed confidence in eliminating miscommunications with payors to prevent prior period adjustments moving forward.

Overall, P3 Health Partners is focusing on stabilizing its operations and improving financial performance, with a cautious but optimistic outlook for 2026 amid ongoing challenges and adjustments in the healthcare landscape.